NCT03018925View on ClinicalTrials.gov

Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

October 31, 2020

Conditions
Ulcerative Colitis
Interventions
DRUG

Golimumab

The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.

Trial Locations (1)

17007

Hospital Doctor Josep Trueta, Girona

All Listed Sponsors
lead

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

OTHER

NCT03018925 - Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis | Biotech Hunter | Biotech Hunter